Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients

J. L. Oblinger, D. K. Pearl, C. L. Boardman, H. Saqr, T. W. Prior, B. W. Scheithauer, R. B. Jenkins, P. C. Burger, A. J. Yates

Research output: Contribution to journalArticle

Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive primary human brain tumour in adults with an average survival of 11 months. The 2-year survival is less than 10%, and only a small proportion of patients are alive at 3 years. Despite improved treatment strategies and aggressive therapy, the prognosis of GBM has changed little in past decades. Thus, any test that can reliably and rapidly diagnose the tumour and predict patient survival could be a valuable tool. Herein we report the use of quantitative real-time polymerase chain reaction (PCR) to quantify five glycosyltransferase transcripts in gliomas. Our results indicate that measuring GM1 synthase (β-1,3 galactosyltransferase) mRNA may provide a useful method for segregating GBMs from other types of gliomas. In these studies, 97% of gliomas (36/37 tumours) below a threshold value had a diagnosis of GBM compared with 49% (52/106 tumours) above the threshold. More importantly, the increased expression of GD3 synthase mRNA in combination with decreased GalNAcT message correlated with increased survival in 79 GBM patients (proportional hazards model controlling for age, P = 0.02). These data were further corroborated by a data analysis from one of our previous studies on gangliosides of 80 GBMs, in which increased amounts of GM3 and GD3 (which accumulate in the absence of GalNAcT) correlated with a longer survival (P <0.01). Thus, measuring GalNAcT and GD3 transcripts may provide a rapid method to assess prognosis in GBM patients. In summary, the data indicate that measuring glycosyltransferase mRNA levels by real-time PCR may be clinically useful for determining both diagnosis and prognosis in GBM patients.

Original languageEnglish (US)
Pages (from-to)410-418
Number of pages9
JournalNeuropathology and Applied Neurobiology
Volume32
Issue number4
DOIs
StatePublished - Aug 2006

Fingerprint

Glycosyltransferases
Glioblastoma
Messenger RNA
Survival
Glioma
Real-Time Polymerase Chain Reaction
Galactosyltransferases
Neoplasms
Gangliosides
Proportional Hazards Models
Brain Neoplasms
Therapeutics

Keywords

  • Diagnosis
  • Gangliosides
  • Glioblastoma multiforme
  • Glycosyltransferases
  • Prognosis
  • Real-time reverse transcription polymerase chain reaction

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Oblinger, J. L., Pearl, D. K., Boardman, C. L., Saqr, H., Prior, T. W., Scheithauer, B. W., ... Yates, A. J. (2006). Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients. Neuropathology and Applied Neurobiology, 32(4), 410-418. https://doi.org/10.1111/j.1365-2990.2006.00742.x

Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients. / Oblinger, J. L.; Pearl, D. K.; Boardman, C. L.; Saqr, H.; Prior, T. W.; Scheithauer, B. W.; Jenkins, R. B.; Burger, P. C.; Yates, A. J.

In: Neuropathology and Applied Neurobiology, Vol. 32, No. 4, 08.2006, p. 410-418.

Research output: Contribution to journalArticle

Oblinger, JL, Pearl, DK, Boardman, CL, Saqr, H, Prior, TW, Scheithauer, BW, Jenkins, RB, Burger, PC & Yates, AJ 2006, 'Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients', Neuropathology and Applied Neurobiology, vol. 32, no. 4, pp. 410-418. https://doi.org/10.1111/j.1365-2990.2006.00742.x
Oblinger, J. L. ; Pearl, D. K. ; Boardman, C. L. ; Saqr, H. ; Prior, T. W. ; Scheithauer, B. W. ; Jenkins, R. B. ; Burger, P. C. ; Yates, A. J. / Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients. In: Neuropathology and Applied Neurobiology. 2006 ; Vol. 32, No. 4. pp. 410-418.
@article{1c918f7aeecf402ea5b4b09fb853a996,
title = "Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients",
abstract = "Glioblastoma multiforme (GBM) is the most common and aggressive primary human brain tumour in adults with an average survival of 11 months. The 2-year survival is less than 10{\%}, and only a small proportion of patients are alive at 3 years. Despite improved treatment strategies and aggressive therapy, the prognosis of GBM has changed little in past decades. Thus, any test that can reliably and rapidly diagnose the tumour and predict patient survival could be a valuable tool. Herein we report the use of quantitative real-time polymerase chain reaction (PCR) to quantify five glycosyltransferase transcripts in gliomas. Our results indicate that measuring GM1 synthase (β-1,3 galactosyltransferase) mRNA may provide a useful method for segregating GBMs from other types of gliomas. In these studies, 97{\%} of gliomas (36/37 tumours) below a threshold value had a diagnosis of GBM compared with 49{\%} (52/106 tumours) above the threshold. More importantly, the increased expression of GD3 synthase mRNA in combination with decreased GalNAcT message correlated with increased survival in 79 GBM patients (proportional hazards model controlling for age, P = 0.02). These data were further corroborated by a data analysis from one of our previous studies on gangliosides of 80 GBMs, in which increased amounts of GM3 and GD3 (which accumulate in the absence of GalNAcT) correlated with a longer survival (P <0.01). Thus, measuring GalNAcT and GD3 transcripts may provide a rapid method to assess prognosis in GBM patients. In summary, the data indicate that measuring glycosyltransferase mRNA levels by real-time PCR may be clinically useful for determining both diagnosis and prognosis in GBM patients.",
keywords = "Diagnosis, Gangliosides, Glioblastoma multiforme, Glycosyltransferases, Prognosis, Real-time reverse transcription polymerase chain reaction",
author = "Oblinger, {J. L.} and Pearl, {D. K.} and Boardman, {C. L.} and H. Saqr and Prior, {T. W.} and Scheithauer, {B. W.} and Jenkins, {R. B.} and Burger, {P. C.} and Yates, {A. J.}",
year = "2006",
month = "8",
doi = "10.1111/j.1365-2990.2006.00742.x",
language = "English (US)",
volume = "32",
pages = "410--418",
journal = "Neuropathology and Applied Neurobiology",
issn = "0305-1846",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients

AU - Oblinger, J. L.

AU - Pearl, D. K.

AU - Boardman, C. L.

AU - Saqr, H.

AU - Prior, T. W.

AU - Scheithauer, B. W.

AU - Jenkins, R. B.

AU - Burger, P. C.

AU - Yates, A. J.

PY - 2006/8

Y1 - 2006/8

N2 - Glioblastoma multiforme (GBM) is the most common and aggressive primary human brain tumour in adults with an average survival of 11 months. The 2-year survival is less than 10%, and only a small proportion of patients are alive at 3 years. Despite improved treatment strategies and aggressive therapy, the prognosis of GBM has changed little in past decades. Thus, any test that can reliably and rapidly diagnose the tumour and predict patient survival could be a valuable tool. Herein we report the use of quantitative real-time polymerase chain reaction (PCR) to quantify five glycosyltransferase transcripts in gliomas. Our results indicate that measuring GM1 synthase (β-1,3 galactosyltransferase) mRNA may provide a useful method for segregating GBMs from other types of gliomas. In these studies, 97% of gliomas (36/37 tumours) below a threshold value had a diagnosis of GBM compared with 49% (52/106 tumours) above the threshold. More importantly, the increased expression of GD3 synthase mRNA in combination with decreased GalNAcT message correlated with increased survival in 79 GBM patients (proportional hazards model controlling for age, P = 0.02). These data were further corroborated by a data analysis from one of our previous studies on gangliosides of 80 GBMs, in which increased amounts of GM3 and GD3 (which accumulate in the absence of GalNAcT) correlated with a longer survival (P <0.01). Thus, measuring GalNAcT and GD3 transcripts may provide a rapid method to assess prognosis in GBM patients. In summary, the data indicate that measuring glycosyltransferase mRNA levels by real-time PCR may be clinically useful for determining both diagnosis and prognosis in GBM patients.

AB - Glioblastoma multiforme (GBM) is the most common and aggressive primary human brain tumour in adults with an average survival of 11 months. The 2-year survival is less than 10%, and only a small proportion of patients are alive at 3 years. Despite improved treatment strategies and aggressive therapy, the prognosis of GBM has changed little in past decades. Thus, any test that can reliably and rapidly diagnose the tumour and predict patient survival could be a valuable tool. Herein we report the use of quantitative real-time polymerase chain reaction (PCR) to quantify five glycosyltransferase transcripts in gliomas. Our results indicate that measuring GM1 synthase (β-1,3 galactosyltransferase) mRNA may provide a useful method for segregating GBMs from other types of gliomas. In these studies, 97% of gliomas (36/37 tumours) below a threshold value had a diagnosis of GBM compared with 49% (52/106 tumours) above the threshold. More importantly, the increased expression of GD3 synthase mRNA in combination with decreased GalNAcT message correlated with increased survival in 79 GBM patients (proportional hazards model controlling for age, P = 0.02). These data were further corroborated by a data analysis from one of our previous studies on gangliosides of 80 GBMs, in which increased amounts of GM3 and GD3 (which accumulate in the absence of GalNAcT) correlated with a longer survival (P <0.01). Thus, measuring GalNAcT and GD3 transcripts may provide a rapid method to assess prognosis in GBM patients. In summary, the data indicate that measuring glycosyltransferase mRNA levels by real-time PCR may be clinically useful for determining both diagnosis and prognosis in GBM patients.

KW - Diagnosis

KW - Gangliosides

KW - Glioblastoma multiforme

KW - Glycosyltransferases

KW - Prognosis

KW - Real-time reverse transcription polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=33745739440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745739440&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2990.2006.00742.x

DO - 10.1111/j.1365-2990.2006.00742.x

M3 - Article

VL - 32

SP - 410

EP - 418

JO - Neuropathology and Applied Neurobiology

JF - Neuropathology and Applied Neurobiology

SN - 0305-1846

IS - 4

ER -